IL17A and autoimmune thrombocytopenic purpura: First, the proteomics data obtained from spleen and plasma in mice suggested that IVIG treatment for ITP should primarily focus on modulating the differentiation of T cell lines, T-cell receptor binding, IL-17 signaling pathway, FcγRs mediated phagocytosis, cytokines, chemokines, etc. These findings were consistent with the work of Wang et al. [45], Ding et al. [46], and Segú-Vergés et al. [47].